Skip to main content

Table 2 Descriptive summary of serum utomilumab pharmacokinetic parameter values for Cycle 5

From: A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Parameter, Units

Mogamulizumab 1 mg/kg + Utomilumab, by Dose Groupa

1.2 mg/kg

100 mg

5 mg/kg

n

2

1

2

AUClast, μg·h/mL

907, 1440

2700

1620, 9270

AUClast,(dn), μg·h/mL/mg/kg

756, 1200

2490

323, 1850

Cmax, μg/mL

17.5, 20.0

27.8

86.6, 129

Cmax,(dn), μg/mL/mg/kg

14.6, 16.7

25.6

17.3, 25.8

Ctrough, μg/mL

1.30b

1.16

2.19, 5.48

Tlast, h

335, 336

309

25.1, 170

Tmax h

2.00, 2.03

6.00

1.00, 1.15

  1. aIndividual patient value(s) are presented when N < 3
  2. bOnly 1 patient had quantifiable Ctrough concentrations
  3. AUClast Area under the serum concentration–time profile from time zero to the time of the last quantifiable concentration, Cmax Maximum observed serum concentration, Ctrough Predose concentration during multiple dosing, dn Dose normalized, n Number of patients in the treatment group and contributing to the summary statistics, Tlast Time of last measurable concentration, Tmax Time for Cmax
Back to article page